

### 1.3.1.1 PROFESSIONAL INFORMATION FOR MEDICINES FOR HUMAN USE

#### SCHEDULING STATUS

**S3**

#### PROPRIETARY NAME AND DOSAGE FORM

LENNON ISONIAZID 100 mg (tablets)

LENNON ISONIAZID 200 mg (tablets)

LENNON ISONIAZID 300 mg (tablets)

#### COMPOSITION

LENNON ISONIAZID 100 mg contains 100 mg isoniazid.

*Excipients:*

Colloidal silicon dioxide, hydrogenated vegetable oil (Sterotex), maize starch, mucilage acacia 30 %, sodium starch glycollate.

LENNON ISONIAZID 200 mg contains 200 mg isoniazid.

*Excipients:*

Acacia mucilage 30 %, Lake erythrosine (C.I. No.45430), maize starch, magnesium stearate, powdered vegetable stearine, sodium starch glycollate.

LENNON ISONIAZID 300 mg contains 300 mg isoniazid.

*Excipients:*

Dye yellow No. 137 (C.I. No. 19140), maize starch, mucilage acacia 30 %, powdered vegetable stearine, sodium starch glycollate.

## **PHARMACOLOGICAL CLASSIFICATION**

A.20.2.3. Tuberculostatics

## **PHARMACOLOGICAL ACTION**

Isoniazid is a synthetic, bactericidal antitubercular agent, which is active against many mycobacteria, primarily those that are actively dividing. Its exact mechanism of action is not known, but it may relate to inhibition of mycolic acid synthesis and disruption of the cell wall in susceptible organisms.

It is readily absorbed from the gastrointestinal tract following oral administration, but may however undergo significant first pass metabolism. The primary metabolic route is acetylation. Absorption and bio-availability are reduced when administered with food. The plasma half-life for isoniazid ranges from about 1 to 4 hours. It is widely distributed to all fluids and tissues, including cerebrospinal fluid (CSF), pleural and ascitic fluids, skin, sputum, saliva, lungs, muscle, and caseous tissue. It crosses the placenta and is excreted in the breast milk. Approximately 75 to 95 % is excreted by the kidneys within 24 hours, mainly as metabolites. Small amounts are excreted in the faeces.

## **INDICATIONS**

LENNON ISONIAZID is used in the prophylaxis and treatment of pulmonary and extrapulmonary tuberculosis. It is administered with other antituberculous agents such as rifampicin and pyrazinamide.

## **CONTRAINDICATIONS**

The risk-benefit should be considered when the following medical problems exist:

- Hypersensitivity to isoniazid, ethionamide, pyrazinamide, niacin, or other chemically related compounds or to any of the excipients (see COMPOSITION).
- Alcoholism.

- Hepatic function impairment.
- Severe renal failure.
- Seizure disorders.
- Pregnancy and lactation (see PREGNANCY AND LACTATION).

## **WARNINGS AND SPECIAL PRECAUTIONS**

LENNON ISONIAZID may cause severe and sometimes fatal age-related hepatitis. If signs and symptoms of hepatotoxicity occur, treatment should be promptly discontinued.

The administration of 10 mg pyridoxine daily is recommended to prevent or minimize symptoms of peripheral neuritis, as well as for those who are diabetic, alcoholic, malnourished, uraemic, or pregnant.

Periodic eye examinations during treatment is recommended.

LENNON ISONIAZID 300 mg contains tartrazine which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of tartrazine sensitivity in the general population is currently thought to be low, it is frequently seen in patients who also have aspirin sensitivity (see COMPOSITION).

## **INTERACTIONS**

Adverse reactions have occurred when LENNON ISONIAZID has been given anti-epileptics such as phenytoin, primidone, carbamazepine, and ethosuximide, with benzodiazepines, such as diazepam or triazolam, and with warfarin. Theophylline plasma concentrations have increased following several weeks of insomnia administration.

Concurrent administration of LENNON ISONIAZID and rifampicin may lead to a higher incidence of hepatotoxicity, and increased central nervous system adverse effects have

occurred when LENNON ISONIAZID is given with cycloserine or disulfiram. Hepatotoxic reactions have been reported when paracetamol is given concurrently with LENNON ISONIAZID. Palpitations, headache, conjunctival irritation, severe flushing, tachycardia, tachypnoea, and sweating have been reported following ingestion of cheese, red wine, and some fish.

LENNON ISONIAZID itself may be affected by other compounds, namely alcohol, aminosalicic acid, antacids, corticosteroids, ketoconazole, propranolol, pyridoxine and sodium and sodium salicylate.

### **PREGNANCY AND LACTATION**

LENNON ISONIAZID should be avoided during pregnancy and lactation (see CONTRAINDICATIONS).

### **DOSAGE AND DIRECTIONS FOR USE**

#### ***Adult and Adolescent Dose***

**Prophylaxis:** 300 mg once daily.

**Treatment:** In combination with other antituberculars: 300 mg once daily for the entire treatment period or 15 mg per kg of body weight (up to 900 mg) twice a week for the remainder of therapy after the initial two months of 300 mg once a day.

#### ***Paediatric Dose:***

**Prophylaxis:** 10 mg per kg of body weight, up to 300 mg, once daily.

**Treatment:** In combination with other antituberculars: 10 to 20 mg per kg of body weight, up to 300 mg, once daily.

LENNON ISONIAZID may be taken with meals if gastrointestinal irritation occurs, but oral absorption may be reduced. Patients who are slow acetylators may be more prone to adverse effects and may require lower than usual doses. Tuberculosis therapy must be continued for 6 months to 2 years, depending on the treatment given.

## **SIDE EFFECTS**

Adverse effects include gastrointestinal irritation, nausea, pellagra, hyperglycaemia, metabolic acidosis, Lupus-like syndrome, rheumatoid syndrome, urinary retention and gynaecomastia.

Other frequent side effects include hepatitis prodromal symptoms (loss of appetite, nausea or vomiting, unusual tiredness or weakness), hepatitis and peripheral neuritis.

Neurological adverse effects include psychotic reactions and convulsions.

Side effects occurring less frequently include blood dyscrasias, hypersensitivity reactions (fever, skin rashes, joint pain), neurotoxicity (psychotic reactions and convulsions), and optic neuritis.

## **KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT**

Patients may be asymptomatic for 30 minutes to 2 hours after an acute overdose. Early symptoms include, nausea, vomiting, dizziness, slurred speech, lethargy, disorientation and hyper-reflexia. Seizure usually occur within 1 to 3 hours after ingestion and are often repetitive and refractory to usual anticonvulsants.

Metabolic acidosis occurs within a few hours, Hyperglycaemia, glycosuria and ketonuria have been reported. Treatment for overdose consists of gastric lavage following intubation and the control of convulsions by diazepam given intravenously, together with large doses of pyridoxine. Metabolic acidosis is corrected with sodium bicarbonate.

## **IDENTIFICATION**

LENNON ISONIAZID 100 mg: A white to off-white, round, biconvex tablet with slightly bevelled edges, bisected and marked with D above the bisect line and 97 below the bisect line on one side of the tablet, and plain on the other side.

LENNON ISONIAZID 200 mg: Pink, biconvex, bisected tablets.

LENNON ISONIAZID 300 mg : Yellow, biconvex, bisected tablets.

## **PRESENTATION**

LENNON ISONIAZID 100 mg: Tablets are packed in white polypropylene securitainers with snap-on caps, rayon and desiccant disc.

LENNON ISONIAZID 200 mg : Plastic containers of 100,1000 and 10 000 tablets and tins of 5000 tablets.

LENNON ISONIAZID 300 mg: Plastic containers of 100 tablets and tins of 5000 tablets.

Not all packs and pack sizes are necessarily marketed.

## **STORAGE INSTRUCTIONS**

Store at or below 25°C.

Protect from light.

Keep in the original container until required for use.

**KEEP OUT OF REACH OF CHILDREN.**

## **REGISTRATION NUMBER**

LENNON ISONIAZID 100 mg: A0320

LENNON ISONIAZID 200 mg: J/20.2.3/58

LENNON ISONIAZID 300 mg: J/20.2.3/59

## **NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION**

PHARMACARE LIMITED

Healthcare Park  
Woodlands Drive  
Woodmead 2191

**DATE OF PUBLICATION OF THE PACKAGE INSERT**

5 March 1979

ZA\_LEISONTAB\_7903\_01